Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 5/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 2/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.40 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.40 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8399378 | 0.85 | GAA (0.44) | MCL1GAAMAPTCPA1CPB1 | |
| SCHEMBL24019759 | 0.77 | SIGMAR1 (0.47) | CTSCMCL1MAPTSMN1; SMN2 | |
| SCHEMBL9779725 | 0.77 | SIGMAR1 (0.43) | CTSCMCL1MAPTACP3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9676562 | 0.76 | CYP3A4 (0.44) | CTSCMCL1MAPTACP3SMN1; SMN2 | |
| SCHEMBL18762531 | 0.75 | CTSC (0.44) | CTSCMCL1MAPTLMNAALDH1A1 | |
| SCHEMBL7418478 | 0.74 | TACR1 (0.55) | — | |
| SCHEMBL4849306 | 0.74 | SIGMAR1 (0.61) | GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL60484 | 0.74 | GAA (0.62) | GAAMAPTCPA1CPB1CPA3 | |
| SCHEMBL2852187 | 0.74 | SIGMAR1 (0.61) | GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31267566 | 0.74 | GAA (0.62) | GAAMAPTCPA1CPB1CPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101053-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | MERCK CANADA INC. (CA) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101053-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | CTSL, CTSS, CTSZ | CTSC 13/4885MCL1 2048/4885GAA 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.